Skip to main content
Premium Trial:

Request an Annual Quote

Great Basin Files to Raise $10M

NEW YORK (GenomeWeb) – Great Basin Scientific today filed with the US Securities and Exchange Commission to raise $10 million through an offering of securities units comprising stocks and warrants.

In Great Basin's S-1 registration, the firm said it will offer $8 million in Class A units, consisting of shares of the firm's common stock and Series J Warrants, and $2 million in Class B units, comprised of one prefunded Series K warrant to purchase an unspecified number of shares of its common stock together with Series J Warrants.

The funds raised in this offering will be used to fund the firm's operations for up to four months following the closing of the offering. This will include the continued expansion of sales of the firm's four currently approved tests and the regulatory process seeking approval for two tests currently under review by the US Food and Drug Administration, according to the registration statement.

The company has not priced the units or said how many A or B units it plans to offer.

The firm withdrew a planned S-1 registration statement last month after determining operating cash needs were below forecast and additional funds were unnecessary. Last week it announced a restructuring plan that eliminated about 50 jobs, and it also reached an agreement with holders of its 2016 convertible notes to reduce the notes' principal by about half, stating that the original funding available under the terms of the notes was greater than the company required.

Great Basin went public in October of 2014, but was delisted from the Nasdaq last year and now trades on the over-the-counter market.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.